论文部分内容阅读
目的探讨并分析低分子肝素钠对短暂性脑缺血发作(TIA)的临床疗效。方法对我院最近两年收治的60例TIA患者进行随机分组:实验组和对照组。对照组30例患者主要口服抗血小板聚集剂(阿司匹林肠溶片)进行治疗,实验组30例患者在对照组的治疗基础上加用抗凝药物低分子肝素钠治疗,在治疗过程中比较两组患者的临床疗效,并在治疗前后监测凝血酶原时间(PT)、活化部分凝血酶时间(APTT)、血小板计数(PLT)等血流动力学及血液成分指标的变化。结果治疗组治愈12例,治疗有效16例,总有效率93.3%,显著高于对照组的66.7%(P<0.05);且治疗组的PT、APTT、PLT等指标改善显著优于对照组(P<0.05),未出现明显出血等不良反应。结论低分子肝素钠治疗TIA有着比较明显的疗效,可有效预防TIA发作,是较为安全可靠的药物。
Objective To investigate and analyze the clinical effect of low molecular weight heparin on transient ischemic attack (TIA). Methods Sixty TIA patients admitted to our hospital in recent two years were randomly divided into experimental group and control group. Control group of 30 patients were mainly oral antiplatelet aggregation agent (aspirin enteric-coated tablets) for treatment of experimental group of 30 patients in the control group based on the treatment of anticoagulant drugs with low molecular weight heparin sodium treatment in the treatment of two groups The clinical efficacy was monitored before and after treatment. The hemodynamic parameters such as prothrombin time (PT), activated partial thromboplastin time (APTT) and platelet count (PLT) were also measured before and after treatment. Results In the treatment group, 12 cases were cured and 16 cases were cured. The total effective rate was 93.3%, which was significantly higher than that of the control group (66.7%) (P <0.05). The indexes of PT, APTT and PLT in the treatment group were significantly better than those in the control group P <0.05), no obvious bleeding and other adverse reactions. Conclusion Low molecular weight heparin treatment of TIA has a more obvious effect, which can effectively prevent the onset of TIA, is a more safe and reliable drug.